Contents

for authors

Cart

quick search

Cart

Your cart is empty

View cart

quick search

Vol. 29, Issue 4 (October-December 2011)

Treatment of nonalcoholic fatty liver disease in children

Treatment of nonalcoholic fatty liver disease in children

Nutritional Therapy Metabolism 2011; 29(4): 157 - 167

Article Type: REVIEW

DOI:10.5301/NTM.2012.9661

Authors

Tudor Lucian Pop, Ana Stefanescu, Nicolae Miu

Corresponding author

  • Tudor Lucian Pop
  • Second Pediatric Clinic, Iuliu Haţieganu University of Medicine and Pharmacy
  • 5, Crisan str.
  • 400177 Cluj-Napoca

Abstract

ABSTRACT

Nonalcoholic fatty liver disease has recently become the most frequent cause of chronic liver damage in children, with potential progression towards fibrosis and cirrhosis. The children sometimes complain of abdominal pain, fatigue or malaise, may have hepatomegaly with or without splenomegaly, or may be asymptomatic and laboratory and ultrasound changes are found incidentally or after screening for obesity-related comorbidities; more than 90% of children with nonalcoholic fatty liver disease are obese with central obesity. The diagnosis for nonalcoholic fatty liver disease requires a clinical and histological algorithm.

At present there are no standard recommendations for the treatment of nonalcoholic fatty liver disease. The therapeutic strategies for these patients can be divided into three categories: identification and treatment of metabolic associations (obesity, diabetes mellitus and dyslipidemia); improving insulin resistance through weight loss, physical exercise or drug therapy; and protecting the liver from oxidative stress by using hepatoprotector agents (antioxidants). The treatment of pediatric nonalcoholic fatty liver disease has two goals: to reverse liver disease and to promote healthy growth. The safest treatment choice for children with nonalcoholic fatty liver disease remains diet and regular physical activity. Before the use of drugs, some of which proven effective in adults, can be recommended, new controlled studies assessing their effectiveness and safety in children are necessary.

Article History

Disclosures

Conflict of interest statement: none declared.
Financial support: none.

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

Authors

  • Address for correspondence:
  • Second Pediatric Clinic, Iuliu Haţieganu University of Medicine and Pharmacy
  • 5, Crisan str.
  • tudor.pop@umfcluj.ro

Affiliations

  • Second Pediatric Clinic, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca - Romania

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • If you are not a Subscriber you may:
  • Subscribe to this journal

    Unlimited access to all our archives, 24 hour a day, every day of the week.

    Article price: Eur 36.00

    You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.

  • Claim online access

    If you hold a Society membership and you have never accessed the website claim online access to receive your log in credentials

Il testo completo di questo articolo è disponibile come Full Text.

No supplementary material is available for this article.